Patents Assigned to Cypress Bioscience, Inc.
-
Publication number: 20070072946Abstract: The present invention is directed to methods for providing long-term treatment of fibromyalgia syndrome (FMS) by administering a dual re-uptake inhibitor to a patient with FMS. More particularly, the present invention is directed to the long-term treatment of FMS by administering a norepinephrine-serotonin reuptake inhibitor (NSRI) to a patient with FMS.Type: ApplicationFiled: September 26, 2006Publication date: March 29, 2007Applicant: Cypress Bioscience, Inc.Inventors: Srinivas Rao, Michael Gendreau, Jay Kranzler
-
Patent number: 6992110Abstract: The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.Type: GrantFiled: July 18, 2003Date of Patent: January 31, 2006Assignee: Cypress Bioscience, Inc.Inventors: Jay D. Kranzler, Srinivas G. Rao
-
Publication number: 20040229956Abstract: The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.Type: ApplicationFiled: July 18, 2003Publication date: November 18, 2004Applicant: Cypress Bioscience, Inc.Inventors: Jay D. Kranzler, Srinivas G. Rao
-
Publication number: 20040132826Abstract: A once-a-day oral milnacipran modified release formulation has been developed. The formulation comprises an extended release dosage unit (optionally containing the immediate release portion) coated with delayed release coating. The milnacipran composition, when administered orally, first passes through the stomach releasing from zero to less than 10% of the total milnacipran dose and then enters the intestines where drug is released slowly over an extended period of time. The release profile is characterized by a 0.05-4 hours lag time period during which less than 10% of the total milnacipran dose is released followed by a slow or extended release of the remaining drug over a defined period of time. The composition provides in vivo drug plasma levels characterized by Tmax at 4-10 hours and an approximately linear drop-off thereafter and Cmax below 3000 ng/ml, preferably below 2000 ng/ml, and most preferably below 1000 ng/ml.Type: ApplicationFiled: October 22, 2003Publication date: July 8, 2004Applicants: Collegium Pharmaceutical, Inc., Cypress Bioscience, Inc.Inventors: Jane Hirsh, Roman V. Rariy, Shubha Chungi, Michael Heffernan, Srinivas G. Rao
-
Publication number: 20040106681Abstract: The present invention provides a method to treat neurological disorders. The method includes, e.g., administering higher daily dosages of anti-depressant. The higher daily dosages result in an improved efficacy of the drug, the maintenance of a positive patient toleration, the maintenance of a positive patient safety profile (e.g., dose limiting toxicity), a suitable peak plasma concentration (Cmax) of drug, and/or a once-a-day (QD) as opposed to twice-a-day (BID) administration. Applicant have discovered that increased daily dosages anti-depressant that would normally evoke adverse effects can be administered without the negative patient tolerability (i.e., adverse reactions) by escalating dosages over time. Such escalation dosages provide more efficacious amounts of anti-depressant than would otherwise be permitted. Similarly, higher levels of circulating drug are possible in patients by administering the compound in divided doses over the course of a day rather than once a day.Type: ApplicationFiled: October 3, 2003Publication date: June 3, 2004Applicant: Cypress Bioscience, Inc.Inventors: Srinivas G. Rao, Jay D. Kranzler, R. Michael Gendreau
-
Publication number: 20040034101Abstract: Methods for the prevention or treatment of a typical depression secondary to pain (DSP) have been developed. The method generally involves administering an effective amount of a monoamine re uptake inhibitor to treat or prevent symptoms of DSP. In a preferred embodiment, a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor (SRNI) compound of a specific type, or a pharmaceutically acceptable salt thereof is administered. The most preferred SNRI compounds are non-tricyclic SNRIs, wherein serotonin reuptake inhibition is greater than norepinephrine reuptake inhibition; and NSRIs, wherein norepinephrine reuptake inhibition is greater than serotonin reuptake inhibition. The most preferred compound is milnacipran or a bioequivalent or pharmaceutically acceptable salt thereof. Other preferred compounds are duloxetine and venlafaxine or a bioequivalent or pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 24, 2003Publication date: February 19, 2004Applicant: Cypress Bioscience, Inc.Inventors: Srinivas G. Rao, Jay D. Kranzler
-
Publication number: 20040019116Abstract: The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.Type: ApplicationFiled: July 18, 2003Publication date: January 29, 2004Applicant: Cypress Bioscience, Inc.Inventors: Jay D. Kranzler, Srinivas G. Rao
-
Publication number: 20030232805Abstract: Methods for the prevention or treatment of stress-related disorders by administering a therapeutically effective amount of a dual serotonin/norepinephrine reuptake inhibitor to an individual under stress are described. A triple monoamine reuptake inhibitor for serotonin/noradrenaline/dopamine may also be administered to an individual at risk for a stress-related disorder. In a preferred embodiment the compound is milnacipran and is prophylactically administered at an effective amount to delay or prevent stress-related disorders in an individual at risk.Type: ApplicationFiled: April 24, 2003Publication date: December 18, 2003Applicant: Cypress Bioscience, Inc.Inventors: Jay D. Kranzler, Srinivas G. Rao
-
Publication number: 20030203055Abstract: The present invention provides a method of treating a visceral pain syndromes in a mammal. The method includes administering to the mammal an effective amount of a selective norepinephrine (NE)-serotonin (5-HT) reuptake inhibitor (NSRI), e.g., milnacipran.Type: ApplicationFiled: March 17, 2003Publication date: October 30, 2003Applicant: Cypress Bioscience, Inc.Inventors: Srinivas G. Rao, Jay D. Kranzler
-
Patent number: 6635675Abstract: The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject comprising administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and a greater inhibition of norepinephrine reuptake than serotonin reuptake, and wherein said compound is not administered adjunctively with phenylalanine or tyrosine. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.Type: GrantFiled: November 5, 2001Date of Patent: October 21, 2003Assignee: Cypress Bioscience, Inc.Inventors: Jay D. Kranzler, Srinivas G. Rao
-
Patent number: 6602911Abstract: The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.Type: GrantFiled: December 19, 2001Date of Patent: August 5, 2003Assignee: Cypress Bioscience, Inc.Inventors: Jay D. Kranzler, Srinivas G. Rao
-
Patent number: 5782792Abstract: Rheumatoid arthritis is treated by the extra corporeal removal of IgG and IgG-containing circulating immune complexes from the patient's blood. Removal is preferably accomplished by exposing the blood or blood plasma to a protein A immunoadsorbent which binds to IgG-containing immune complexes with high affinity.Type: GrantFiled: December 12, 1994Date of Patent: July 21, 1998Assignee: Cypress Bioscience, Inc.Inventors: Frank R. Jones, Harry W. Snyder, Jr., Joseph P. Balint, Jr.
-
Patent number: 5733254Abstract: Immune thrombocytopenic purpura is treated by removal of IgG and circulating immune complexes from the patient's blood. Removal is accomplished by exposing the blood or blood plasma to an immunoadsorbent capable of removing IgG and its complexes. The immunoadsorbent comprises a suitable solid phase coupled to a receptor capable of binding IgG and its complexes, such as protein A. The IgG and its complexes are then removed by the extracorporeal exposure of the patient's blood to the immunoadsorbent, either in a continuous or discontinuous process. In the continuous process, the blood is removed in a steady flow from the patient, separated into its plasma and cellular components, the plasma treated, and the combined cellular components and treated plasma reinfused to the patient.Type: GrantFiled: May 1, 1995Date of Patent: March 31, 1998Assignee: Cypress Bioscience, Inc.Inventors: Frank R. Jones, Joseph P. Balint, Jr., Harry W. Snyder